Ebola and Marburg vaccine candidate


Bavarian Nordic has collaborated with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for several years to advance its MVA-BN technology to develop a multivalent vaccine against two filoviruses, Ebola and Marburg, for which no approved treatment or vaccine exist.

The multivalent strain, MVA-BN Filo, contains the glycoprotein of Ebola Zaire, Ebola Sudan and Marburg. This construct is designed to provide protection from the three most common strains of viral hemorrhagic fevers.

In a study, conducted under NIAID’s preclinical services program, MVA-BN Filo was investigated in a prime-boost regimen with the Ad26.ZEBOV vaccine from Janssen. When both vaccines were administered two months apart, complete protection from death due to Ebola Zaire was achieved. Based on these promising results, Janssen and Bavarian Nordic joined forces to advance the development of this vaccine approach through a collaboration agreement announced in October 2014.

There are currently a number of ongoing safety and immunogenicity trials of MVA-BN Filo in prime-boost regimens with different adenovirus-based vaccines. For an overview of these trials, click here.